

RESEARCH LETTER

Open Access



Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation

Marina Rieder^{1,2}, Tobias Wengenmayer^{1,2}, Dawid Staudacher^{1,2}, Daniel Duerschmied^{1,2} and Alexander Supady^{1,2*}

The treatment of patients with severe COVID-19 requiring support with veno-venous extracorporeal membrane oxygenation (vv-ECMO) is particularly challenging from a medical point of view and consumes a tremendous amount of human, physical, and financial resources. Recommendations for initiation of vv-ECMO in COVID-19 are being developed, though under continuous review [1, 2]. However, despite all therapeutic efforts, these critically ill patients have a high mortality rate according to studies published so far [3, 4].

At our hospital, a major referral center for extracorporeal support, we have treated several COVID-19 patients with vv-ECMO. Knowing interleukin-6 (IL-6) as a predictor of negative outcome, some patients received cytokine adsorption using the CytoSorb® adsorber (CytoSorbents Europe, Berlin, Germany) shortly after initiation of ECMO for up to 72 h [5]. Based on experience in septic patients, the adsorber was exchanged every 24 h [6]. Integration of the adsorber in the ECMO circuit was feasible and safe. Preliminary data from eight cases (4 patients receiving ECMO with cytokine adsorption, the remaining 4 received ECMO without cytokine adsorption) shows that cytokine adsorption may result in a more pronounced decrease of IL-6 after initiation of ECMO (Fig. 1).

Whether this observation can be confirmed in larger cohorts and the degree to which this effect is caused by the adsorber instead of just being a sign of general clinical improvement warrants further investigation.

Finally, whether this translates into improved clinical outcome remains to be shown, either.

Therefore, we set up a clinical trial to further examine this preliminary observation. The CYCOV-II study (cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation) is a randomized, controlled, open-label intervention, multicenter trial comparing cytokine adsorption in ECMO treatment for COVID-19 with a control group receiving standard ECMO treatment without cytokine adsorption (Fig. 2; NCT04385771).




Fig. 1 IL-6 levels within the first 72 h after onset of vv-ECMO in 8 patients. Four patients received vv-ECMO without cytokine adsorption (red), and 4 patients vv-ECMO with cytokine adsorption (blue). Data are presented as mean \pm SEM


* Correspondence: alexander.supady@universitaets-herzzentrum.de

¹Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

²Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



In all participating centers, we plan to randomize all COVID-19 patients receiving vv-ECMO into the study groups. Cytokine adsorption will be performed for 72 h. The primary endpoints of the study are (1) IL-6 reduction by 75% or more after 72 h as compared to the baseline measurement and (2) time to successful ECMO explantation within 30 days after randomization. Further clinically relevant endpoints, such as ventilator free days, days on intensive care unit, and overall survival time, will be assessed as secondary endpoints.

With this study, we expect to clarify whether cytokine adsorption is beneficial in severely affected COVID-19 patients requiring vv-ECMO support.

Acknowledgements

None.

Authors' contributions

A Supady and D Duerschmied designed the study. The data collection and evaluation were conducted by M Rieder and A Supady. T Wengenmayer and D Staudacher supported in the study design, data collection, and evaluation. M Rieder and A Supady wrote the first draft of the manuscript. The author(s) read and approved the final manuscript.

Funding

This work was financed by internal funds from the participating institutions.

Availability of data and materials

All data will be available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Data collection was approved by the institutional ethics committee of the University of Freiburg (EK 168/20), and informed consent was obtained from all participants or legal representatives.

Consent for publication

Not applicable.

Competing interests

Alexander Supady and Daniel Duerschmied received speakers' honoraria from CytoSorbents, the manufacturer of the CytoSorb device. The Department of Cardiology and Angiology I received a research grant from CytoSorbents.

Received: 2 June 2020 Accepted: 1 July 2020

Published online: 14 July 2020

References

1. Rajagopal K, Keller SP, Akkanti B, Bime C, Loyalka P, Cheema FH, Zwischenberger JB, El Banayosy A, Pappalardo F, Slaughter MS, et al. Advanced pulmonary and cardiac support of COVID-19 patients: emerging recommendations from ASAIO-A "living working document". *ASAIO J.* 2020; 66(6):588–98.
2. Shekar K, Badulak J, Peek G, Boeken U, Dalton HJ, Arora L, Zakhary B, Ramanathan K, Starr J, Akkanti B, et al. Extracorporeal life support organization COVID-19 interim guidelines. *ASAIO J.* 2020. Online ahead of print.
3. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Jonathan H *et al*: Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet.* 2020;395(10239):1763–70.
4. Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. *J Crit Care.* 2020;58:27–8.
5. Ruan Q, Yang K, Wang W, Jiang L, Song J: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;46(5):846–8.
6. Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. *Crit Care.* 2017;21(1):74.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.